Humrahi

Mumbai, India Founded: 2023 • Age: 3 yrs Listed
Delivers an app-based program for effective diabetes management and patient support.
Request Access
Report Incorrect Data
Page last updated

About Humrahi

Humrahi is a publicly listed company based in Mumbai (India) founded in 2023. It delivers an app-based program for effective diabetes management and patient support. It operates on a B2C model. The company has 19,688 employees. Its Indian entity Lupin Limited reported revenue of ₹29,039 Cr. Its focus areas include Digital Health, Patient Support and Diabetes Management. Its competitors include Freedom from Diabetes, Oxyjon and Ayur.AI; 1 of its 3 listed competitors has raised funding.

Company details

Humrahi delivers an app-based program for effective diabetes management and patient support, focusing on providing healthcare solutions, providing digital health services, patient support, and diabetes management. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets.

  • Headquarters Mumbai, India
  • Employees 19,688
  • Stage Public
  • Sectors
    Healthcare
  • Website humrahi.co.in
  • Social Facebook
  • Legal Name Lupin Limited
  • Date of Incorporation 01 Mar, 1983
  • Jurisdiction Mumbai, Maharashtra, India
Operational Areas
Healthcare → Diabetes
Key Metrics
  • Market Cap
    ₹87,891 Cr

    LUPIN · NSE

  • Share Price
    ₹1,928.90

    +0.36% today

  • Revenue
    ₹27,958 Cr

    FY 2025-26 · +23.1% YoY

  • EBITDA
    ₹7,602 Cr

    Margin 27.2%

  • Net Profit
    ₹5,688 Cr

    FY 2025-26 · +76.4% YoY

  • P/E (TTM)
    15.1x

    P/B 4.0x

  • ROE
    27.0%

    ROCE 27.4%

  • Debt / Equity
    0.30

    Interest cover 7.0x

  • Employee Count
    19,688

Board of directors of Lupin Limited (Humrahi)

Lupin Limited is the primary company behind Humrahi. The board of Lupin Limited currently have 10 directors; the longest-serving is Vinita Deshbandhu Gupta, appointed in 2001. 21 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Vinita Deshbandhu Gupta
DIN 00058631
Whole-time director17 Aug 200125 yrs 2 moLupin Limited
Nilesh Deshbandhu Gupta
DIN 01734642
Managing Director01 Sep 201313 yrs 1 moLupin Limited
Manju Deshbandhu Gupta
DIN 00209461
Director01 Apr 201412 yrs 6 moLupin Limited
Ramesh Swaminathan
DIN 01833346
Whole-time director26 Mar 20206 yrs 6 moLupin Limited
Kanwar Bir Singh Anand
DIN 03518282
Director12 Aug 20206 yrs 2 moLupin Limited
Mark Daniel Mc Dade
DIN 09037255
Director28 Jan 20215 yrs 8 moLupin Limited
Jeffrey Bruce Kindler
DIN 10592395
Director06 May 20242 yrs 5 moLupin Limited
Alfonso Martin Gimenez Zulueta
DIN 10597962
Director06 May 20242 yrs 5 moLupin Limited
Punita Lal
DIN 03412604
Director14 May 20251 yr 5 moLupin Limited
Anand Kripalu
DIN 00118324
Director01 Feb 20268 moLupin Limited

IPO & Listings of Humrahi

Humrahi is a publicly listed company on the NSE with ticker symbol LUPIN in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNSE: LUPIN
  • Listed entityLupin Limited
  • Exchange sectorPharmaceuticals

Financials of Humrahi

Exchange-reported figures of Lupin Limited, the listed company behind Humrahi (NSE: LUPIN).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹27,958 Cr
+23.1% YoY
EBITDA
₹7,602 Cr
+44.0% YoY
Profit After Tax
₹5,688 Cr
+76.4% YoY
Net Worth
₹22,448 Cr
+30.5% YoY
Total Assets
₹29,973 Cr
+27.9% YoY
Total Debt
₹6,616 Cr
+21.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue27,95822,70820,01116,64216,40515,16315,375
Revenue growth+23.1%+13.5%+20.3%+1.4%+8.2%-1.4%-
EBITDA7,6025,2783,8001,7212192,5671,603
EBITDA margin+27.2%+23.2%+19.0%+10.3%+1.3%+16.9%+10.4%
Profit before tax6,8734,0152,422716(1,372)1,676887
Net profit5,6883,2251,892410(1,561)1,177(470)
Net profit margin+20.3%+14.2%+9.5%+2.5%-9.5%+7.8%-3.1%
EPS (₹)116.6471.8742.019.45(33.62)26.81(5.95)
Balance sheet
Total assets29,97323,43418,01617,78917,09919,71120,071
Net worth22,44817,20414,29012,46412,15313,80312,537
Total debt6,6165,4482,9224,5424,1584,7836,305
Cash & bank5,6533,1421,2031,2931,0981,7422,454
Net working capital12,27710,1956,8667,0747,1537,9408,362
Cash flow
Cash from operations7,3343,0003,6481,8973671,8221,469
Cash from investing(3,865)(4,172)(1,712)(1,287)1,292(1,240)1,107
Cash from financing(846)1,732(2,184)(337)(1,572)(1,885)(891)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue8,2777,4757,1687,0486,2685,6675,7685,673
Revenue growth (YoY)+32.0%+31.9%+24.3%+24.2%+11.9%---
Other income13014111590.0079.0456.9553.7142.29
EBITDA2,4502,3541,8352,3411,7271,3211,3561,340
EBITDA margin+29.8%+31.8%+25.8%+34.3%+28.0%+23.8%+24.1%+24.4%
Depreciation453447313317299393271257
Interest11012011510891.7689.1066.8970.87
Profit before tax2,0171,9281,5222,0071,4168961,0711,055
Tax600459342522194113212195
Net profit1,4171,4691,1811,4851,221782859859
EPS (₹)30.8934.7525.6732.2826.6216.8718.6918.64
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue19,51316,96814,66611,25911,77211,05611,026
Revenue growth+15.0%+15.7%+30.3%-4.4%+6.5%+0.3%-
EBITDA7,1765,3163,4509642092,0441,148
EBITDA margin+36.8%+31.3%+23.5%+8.6%+1.8%+18.5%+10.4%
Profit before tax7,6944,8372,785527(162)1,6301,052
Net profit5,7744,0002,302411(219)1,2171,153
Net profit margin+29.6%+23.6%+15.7%+3.7%-1.9%+11.0%+10.5%
EPS (₹)139.2587.0151.049.35(4.15)27.7416.06
Balance sheet
Total assets31,87325,03721,13519,55419,43919,40917,937
Net worth30,13424,27820,60318,41218,15018,56617,473
Total debt1,1152501057499514855.83
Cash & bank12845913910164.562841,306
Net working capital8,0627,6514,8474,1874,9285,0645,959
Cash flow
Cash from operations5,5402,4452,5041,7941511,5702,219
Cash from investing(5,649)(1,766)(1,599)(1,269)(372)(2,508)(740)
Cash from financing(121)(460)(867)(498)102(53.17)(368)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue7,1725,2354,5014,0685,7094,4864,2084,106
Revenue growth (YoY)+25.6%+16.7%+7.0%-0.9%+37.0%---
Other income10253799.8066354.1448.7955.3032.62
Total expenses3,4392,9533,5182,8932,9792,7402,8742,991
EBITDA3,7332,2829831,1762,7301,7461,3341,115
EBITDA margin+52.5%+44.3%+22.2%+30.5%+48.7%+39.8%+32.9%+28.4%
Depreciation190177179175177208153146
Interest35.5638.7736.0227.7818.9033.8519.5517.55
Profit before tax3,6102,6028681,6362,5881,5531,217984
Tax895439150278460262232176

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 24 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue8,2777,4757,1687,0486,2685,6675,7685,673
Revenue growth (YoY)+32.0%+31.9%+24.3%+24.2%+11.9%---
Other income13014111590.0079.0456.9553.7142.29
EBITDA2,4502,3541,8352,3411,7271,3211,3561,340
EBITDA margin+29.8%+31.8%+25.8%+34.3%+28.0%+23.8%+24.1%+24.4%
Depreciation453447313317299393271257
Interest11012011510891.7689.1066.8970.87
Profit before tax2,0171,9281,5222,0071,4168961,0711,055
Tax600459342522194113212195
Net profit1,4171,4691,1811,4851,221782859859
EPS (₹)30.8934.7525.6732.2826.6216.8718.6918.64
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue27,95822,70820,01116,64216,40515,16315,375
Revenue growth+23.1%+13.5%+20.3%+1.4%+8.2%-1.4%-
Other income1,081202131151210138618
Total expenses20,35617,43016,21114,92116,18712,59613,772
Employee cost4,5753,9643,4953,0872,9892,8262,987
EBITDA7,6025,2783,8001,7212192,5671,603
EBITDA margin+27.2%+23.2%+19.0%+10.3%+1.3%+16.9%+10.4%
Depreciation1,3761,1691,1978811,659887970
Interest434295312274143141363
Profit before tax6,8734,0152,422716(1,372)1,676887
Tax1,5177094872691374491,157
Net profit5,6883,2251,892410(1,561)1,177(470)
Net profit margin+20.3%+14.2%+9.5%+2.5%-9.5%+7.8%-3.1%
EPS (₹)116.6471.8742.019.45(33.62)26.81(5.95)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital91.4491.3291.1491.0090.9090.7490.60
Reserves & surplus22,35717,11214,19912,37412,06213,71212,446
Shareholders' funds (net worth)22,44817,20414,29012,46412,15313,80312,537
Minority interest65.1090.8583.1678.3268.7154.9744.46
Secured loans2,6602,3960.000.00142243176
Unsecured loans3,9563,0522,9224,5424,0174,5406,130
Total debt6,6165,4482,9224,5424,1584,7836,305
Total liabilities29,97323,43418,01617,78917,09919,71120,071
Assets
Gross block23,21720,18419,66518,07715,99014,72714,160
Net block10,9949,7198,8788,3557,3827,8817,938
Capital work in progress1,0165177731,2381,1461,066940
Investments3,6701,1461,0755179002,4552,374
Inventories6,0835,4764,9544,4924,6314,0923,457
Sundry debtors6,6045,4974,6924,4814,2624,4745,446
Cash & bank balances5,6533,1421,2031,2931,0981,7422,454
Loans & advances2,1101,6241,7521,7461,6441,3011,718
Total current assets20,45015,73912,60112,01211,63511,61013,075
Total current liabilities8,1735,5445,7354,9384,4823,6694,713
Net working capital12,27710,1956,8667,0747,1537,9408,362
Total assets29,97323,43418,01617,78917,09919,71120,071
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash1,5449841,2329919262,229544
Net cash from operating activities7,3343,0003,6481,8973671,8221,469
Net cash from investing activities(3,865)(4,172)(1,712)(1,287)1,292(1,240)1,107
Net cash from financing activities(846)1,732(2,184)(337)(1,572)(1,885)(891)
Net change in cash2,624560(248)27387.22(1,303)1,685
Closing cash5,6533,1421,2031,2931,0981,7422,454
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+23.1%+13.5%+20.3%+1.4%+8.2%-1.4%-
EBITDA growth+44.0%+38.9%+120.9%+686.3%-91.5%+60.2%-
PBT growth+71.2%+65.8%+238.1%+9998.0%-+88.9%-41.0%
Net income growth+76.4%+70.5%+361.8%+126.2%-232.6%+350.3%-
Revenue CAGR (3Y)+18.9%+11.5%+9.7%+2.7%+3.8%-1.4%-4.0%
EBITDA CAGR (3Y)+64.1%+188.9%+14.0%+2.4%-53.8%+15.1%-29.1%
Profitability & leverage
Net income margin+19.2%+14.6%+9.7%+2.7%-9.2%+8.1%-1.8%
Return on capital employed+27.4%+20.9%+15.3%+5.7%-6.7%+9.2%+8.1%
Return on net worth+27.0%+21.0%+14.5%+3.6%-11.6%+9.3%-3.6%
Debt / equity0.300.270.280.350.340.420.56
Long-term debt / equity0.110.070.010.010.010.070.32
Interest cover6.987.1811.9732.66-9.928.3757.39
Efficiency & per share
Fixed asset turnover1.291.141.060.981.071.051.03
Inventory turnover4.844.354.243.653.764.024.22
Debtors turnover4.624.464.363.813.763.062.90
EPS (₹)116.6471.8742.019.45(33.62)26.81(5.95)
Dividend per share (₹)18.0012.008.004.004.006.506.00
Book value per share (₹)490.99376.77313.59273.95267.40304.23276.75
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue7,1725,2354,5014,0685,7094,4864,2084,106
Revenue growth (YoY)+25.6%+16.7%+7.0%-0.9%+37.0%---
Other income10253799.8066354.1448.7955.3032.62
Total expenses3,4392,9533,5182,8932,9792,7402,8742,991
EBITDA3,7332,2829831,1762,7301,7461,3341,115
EBITDA margin+52.5%+44.3%+22.2%+30.5%+48.7%+39.8%+32.9%+28.4%
Depreciation190177179175177208153146
Interest35.5638.7736.0227.7818.9033.8519.5517.55
Profit before tax3,6102,6028681,6362,5881,5531,217984
Tax895439150278460262232176
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue19,51316,96814,66611,25911,77211,05611,026
Revenue growth+15.0%+15.7%+30.3%-4.4%+6.5%+0.3%-
Other income1,346253116210217129475
Total expenses12,33611,65211,21610,29511,5639,0129,877
Employee cost2,5452,3122,0961,9341,9181,6961,703
EBITDA7,1765,3163,4509642092,0441,148
EBITDA margin+36.8%+31.3%+23.5%+8.6%+1.8%+18.5%+10.4%
Depreciation707648725548514503519
Interest12184.5056.3598.4473.4740.6252.59
Profit before tax7,6944,8372,785527(162)1,6301,052
Tax1,32886445910227.17371325
Net profit5,7744,0002,302411(219)1,2171,153
Net profit margin+29.6%+23.6%+15.7%+3.7%-1.9%+11.0%+10.5%
EPS (₹)139.2587.0151.049.35(4.15)27.7416.06
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital91.4491.3291.1491.0090.9090.7490.60
Reserves & surplus30,04224,18720,51218,32118,05918,47517,383
Shareholders' funds (net worth)30,13424,27820,60318,41218,15018,56617,473
Secured loans0.000.000.000.000.0050.795.29
Unsecured loans1,1152501057499514350.54
Total debt1,1152501057499514855.83
Total liabilities31,87325,03721,13519,55419,43919,40917,937
Assets
Gross block9,0448,6737,6057,4086,7056,2305,666
Net block4,8734,9464,1134,0223,6903,6393,514
Capital work in progress523278446927947951822
Investments15,62511,95511,5819,9749,5119,5637,456
Inventories3,3513,2272,9693,0193,1772,7082,485
Sundry debtors6,9225,6643,8422,6742,7223,1913,616
Cash & bank balances12845913910164.562841,306
Loans & advances1,7691,5411,5291,3361,6521,1141,102
Total current assets12,17010,8918,4797,1317,6157,2968,509
Total current liabilities4,1083,2403,6322,9442,6872,2332,550
Net working capital8,0627,6514,8474,1874,9285,0645,959
Total assets31,87325,03721,13519,55419,43919,40917,937
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash34212485.6659.101771,16855.94
Net cash from operating activities5,5402,4452,5041,7941511,5702,219
Net cash from investing activities(5,649)(1,766)(1,599)(1,269)(372)(2,508)(740)
Net cash from financing activities(121)(460)(867)(498)102(53.17)(368)
Net change in cash(230)21838.0426.56(118)(991)1,112
Closing cash12845913910164.562841,306
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+15.0%+15.7%+30.3%-4.4%+6.5%+0.3%-
EBITDA growth+35.0%+54.1%+258.0%+360.9%-89.8%+78.0%-
PBT growth+59.1%+73.7%+428.3%+9998.0%-+54.9%-55.1%
Net income growth+44.3%+73.8%+460.5%+287.3%-118.0%+5.5%-
Revenue CAGR (3Y)+20.1%+13.0%+9.9%+0.7%+1.2%+3.1%-4.4%
EBITDA CAGR (3Y)+95.3%+194.0%+19.1%-5.7%-56.3%-0.7%-36.5%
Profitability & leverage
Net income margin+32.6%+23.4%+15.9%+3.8%-1.6%+11.4%+6.6%
Return on capital employed+27.5%+21.3%+14.0%+3.2%-0.6%+9.0%+10.0%
Return on net worth+23.4%+17.7%+11.9%+2.3%-1.2%+7.0%+6.7%
Debt / equity0.030.010.020.050.040.010.00
Long-term debt / equity0.010.010.000.000.010.000.00
Interest cover1.881.812.0723.69-24.082.648.35
Efficiency & per share
Fixed asset turnover2.202.081.951.601.821.862.11
Inventory turnover5.935.484.903.634.004.264.60
Debtors turnover3.103.574.504.173.983.253.00
EPS (₹)139.2587.0151.049.35(4.15)27.7416.06
Dividend per share (₹)18.0012.008.004.004.006.506.00
Book value per share (₹)659.09531.72452.12404.66399.34409.20385.72

Competitors of Humrahi

Humrahi has 3 listed competitors in our database, 1 of them funded. They include Freedom from Diabetes, Oxyjon and Ayur.AI.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Freedom from Diabetes
freedomfromdiabetes.org2013Pune, India17
Offers an online platform with personalized programs for effective diabetes management.
Oxyjon
oxyjon.com2016Gurugram, India$26,16942
Health records are stored online for emergency support and sharing.
Ayur.AI
ayurai.io2021Chennai, India
Platform providing personalized health and wellness solutions
Premium access

Detailed competitors of Humrahi

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Humrahi

Lupin: USFDA Inspection Finds One Observation At Goa Plant, Co Promises To Fix It And Stay Compliant.
Exchange Update • 1 day ago
Lupin: Co Names Brian Savage As New President And Chief Legal Officer, Formerly Worked As EVP And Interim Global CLO At Teva Pharmaceuticals.
Exchange Update • 2 days ago
Lupin Receives U.S. FDA Approval for Phytonadione Injectable Emulsion USP
PR Newswire • 16 days ago
Lupin: Company Gets US FDA Nod for Phytonadione Injectable Emulsion 1 MG/0.5 ML Pre-filled Syringe.
Exchange Update • 17 days ago
Lupin launches fixed-dose triple combination inhaler for COPD in India - The Economic Times
Economic Times • 19 days ago
Lupin Launches World's First Triple Combination Drug for COPD in India
Udaipur Kiran • 19 days ago
Lupin: Launches Formoflo-g MDI, World’s First Fixed-dose Triple Combination Drug For COPD Management
Exchange Update • 19 days ago
Lupin receives tentative U.S. FDA approval for Apixaban Oral Suspension
The Hindu • 27 days ago
Lupin: Co. Receives Tentative Approval From U.s. FDA For Novel Apixaban Oral Suspension
Exchange Update • 27 days ago
Lupin: HSBC on Lupin Maintains Buy with Target Price of ₹2,500 as the current valuation overemphasises known concentration risks while underappreciating the US launch pipeline, with new launches expected to sustain ~US$1.2bn US sales during FY27–29E and continued traction across India and other ex-US segments.
Exchange Update • 1 month ago
Premium access

Complete news archive for Humrahi

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Humrahi

Humrahi was founded in 2023.

Humrahi is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Humrahi has 19,688 employees.

The primary company behind Humrahi, Lupin Limited, reported revenue of ₹29,039 Cr for FY 2026, up 23% year on year.

Humrahi delivers an app-based program for effective diabetes management and patient support, focusing on providing healthcare solutions, providing digital health services, patient support, and diabetes management. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets.

Humrahi's top competitors include Oxyjon, Freedom from Diabetes and Ayur.AI.

Yes, Humrahi is publicly traded on NSE under the ticker symbol LUPIN.

Humrahi operates through Lupin Limited.

The legal entities of Humrahi currently have 11 directors, including Vinita Deshbandhu Gupta, Ramesh Swaminathan, Nilesh Deshbandhu Gupta and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available